Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Total Debt (2019 - 2025)

Historic Total Debt for Tg Therapeutics (TGTX) over the last 7 years, with Q3 2025 value amounting to $245.3 million.

  • Tg Therapeutics' Total Debt rose 48.41% to $245.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $245.3 million, marking a year-over-year increase of 48.41%. This contributed to the annual value of $244.4 million for FY2024, which is 14414.09% up from last year.
  • As of Q3 2025, Tg Therapeutics' Total Debt stood at $245.3 million, which was up 48.41% from $245.0 million recorded in Q2 2025.
  • Tg Therapeutics' 5-year Total Debt high stood at $245.3 million for Q3 2025, and its period low was $16.0 million during Q3 2021.
  • In the last 5 years, Tg Therapeutics' Total Debt had a median value of $97.7 million in 2023 and averaged $117.7 million.
  • Per our database at Business Quant, Tg Therapeutics' Total Debt crashed by 4606.59% in 2021 and then soared by 34462.15% in 2022.
  • Quarter analysis of 5 years shows Tg Therapeutics' Total Debt stood at $67.8 million in 2021, then increased by 4.98% to $71.1 million in 2022, then surged by 40.74% to $100.1 million in 2023, then surged by 144.14% to $244.4 million in 2024, then rose by 0.37% to $245.3 million in 2025.
  • Its Total Debt stands at $245.3 million for Q3 2025, versus $245.0 million for Q2 2025 and $244.7 million for Q1 2025.